Mira Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mira Pharmaceuticals (MIRA).

Price Target Range — 2 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$11Upside to Avg. PT+1515.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Maxim Group	Jason McCarthy	Initiate	Buy	$4
Sep 30, 2024	Rodman & Renshaw	Elemer Piros	Initiate	Buy	$17
Aug 5, 2024	Ascendiant Capital	Edward Woo	Initiate	Buy	$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.

Benzinga Newsdesk

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_05152025_MIRA_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_03132025_MIRA_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Sets $17.75 Price Valuation On Stock

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_111132024_MIRA_Sorensen.pdf

Benzinga Newsdesk

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $17

Rodman & Renshaw analyst Elemer Piros initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

Mira Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Mira Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Sets $17.75 Price Valuation On Stock

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects

PRO
Rodman & Renshaw Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $17

People Also Watch

People Also Watch

Mira Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Mira Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

PROWatching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PROWatching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PROWatching MIRA Pharmaceuticals; Zacks Small-Cap Research Sets $17.75 Price Valuation On Stock

PROWatching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects

PRORodman & Renshaw Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $17

People Also Watch

People Also Watch

PRO
Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Sets $17.75 Price Valuation On Stock

PRO
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects

PRO
Rodman & Renshaw Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $17